References
- Gascon P, Matonti F, Beylerian M, et al. Persistent placoid maculopathy: prognosis factors and functional outcomes. Ocul Immunol Inflamm. 2020;28:1136–1148. doi:10.1080/09273948.2019.1645187.
- Kolomeyer AM, Brucker AJ. Persistent placoid maculopathy: a systematic review. Retina. 2018;38:1881–1895. doi:10.1097/IAE.0000000000002284.
- Golchet PR, Jampol LM, Wilson D, Yannuzzi LA, Ober M, Stroh E. Persistent placoid maculopathy. A new clinical entity. Ophthalmology. 2007;114:1530–1540. doi:10.1016/j.ophtha.2006.10.050.
- Gendy MG, Fawzi AA, Wendel RT, Pieramici DJ, Miller JA, Jampol LM. Multimodal imaging in persistent placoid maculopathy. JAMA Ophthalmol. 2014;132:38–49. doi:10.1001/jamaophthalmol.2013.6310.
- Sassalos TM, Saraf SS, Ober MD. Chorioretinal perfusion in persistent placoid maculopathy. Ophthalmic Surg Lasers Imaging Retina. 2017;48:1026–1031. doi:10.3928/23258160-20171130-12.
- Duman N, Alzaidi Z, Aynekin B, et al. COVID-19 vaccine candidates and vaccine development platforms available worldwide. J Pharm Anal. 2021;11:675–682. doi:10.1016/j.jpha.2021.09.004.
- Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13:e13426. doi:10.7759/cureus.13426.
- Puche N, Hera R, Terrada C, Souied EH. Persistent placoid maculopathy imaged by optical coherence tomography angiography. Retin Cases Brief Rep. 2016;10(4):297–301. doi:10.1097/ICB.0000000000000303.
- Yang JS, Chen CL, Hu YZ, Zeng R. Multiple evanescent white dot syndrome following rabies vaccination: a case report. BMC Ophthalmol. 2018;18:312. doi:10.1186/s12886-018-0968-y.
- Ogino K, Kishi S, Yoshimura N. Multiple evanescent white dot syndrome after human papillomavirus vaccination. Case Rep Ophthalmol. 2014;5:38–43. doi:10.1159/000358870.
- Maleki A, Look-Why S, Manhapra A, Foster CS. COVID-19 recombinant mRNA vaccines and serious ocular inflammatory side effects: real or coincidence? J Ophthalmic Vis Res. 2021;16:490–501. doi:10.18502/jovr.v16i3.9443.
- McElhinney K, McGrath R, Ahern E, O’Connell E. Bilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE) following SARS-CoV-2 mRNA vaccine. BMJ Case Rep. June 1, 2022;15(6):e250346. doi:10.1136/bcr-2022-250346.
- Jakirlic N, Harris T. Case report: acute posterior multifocal placoid pigment epitheliopathy after SARS-CoV-2 vaccination. Optom Vis Sci. June 1, 2022;99(6):534–539. doi:10.1097/OPX.0000000000001900.
- Atas F, Kaya M, Saatci AO. Acute multifocal placoid pigment epitheliopathy-like presentation following the first dose of BNT162B2 COVID-19 vaccination. Ocul Immunol Inflamm. December 3, 2021:1–4. doi:10.1080/09273948.2021.1995763.
- Ishibashi K, Yatsuka H, Haruta M, Kimoto K, Yoshida S, Kubota T. branch retinal artery occlusions, paracentral acute middle maculopathy and acute macular neuroretinopathy after COVID-19 vaccinations. Clin Ophthalmol. 2022;16:987. doi:10.2147/OPTH.S357359.
- Malerbi FK, Schoeps VA, Matos KT. Paracentral acute middle maculopathy in Susac syndrome after dual exposure to SARS-CoV-2 antigen. BMJ Case Rep. May 1, 2022 1;15(5):e247159. doi:10.1136/bcr-2021-247159.
- Dehghani A, Ghanbari H, Houshang-Jahromi MH, Pourazizi M. Paracentral acute middle maculopathy and COVID‐19 vaccination: causation versus coincidence finding. Clin Case Rep. March, 2022;10(3). doi:10.1002/ccr3.5578.
- Vinzamuri S, Pradeep TG, Kotian R. Bilateral paracentral acute middle maculopathy and acute macular neuroretinopathy following COVID-19 vaccination. Indian J Ophthalmol. October, 2021;69(10):2862. doi:10.4103/ijo.IJO_1333_21.
- Hasegawa T, Sannomiya Y, Toyoda M, Maruko I, Iida T. Acute idiopathic maculopathy after COVID-19 vaccination. Am J Ophthalmol Case Rep. June 1, 2022;26:101479. doi:10.1016/j.ajoc.2022.101479.
- Bleicher ID, Brill D, Wu F, Sobrin L, Patel N. Acute idiopathic maculopathy following SARS-CoV-2 vaccination. Ocul Immunol Inflamm. August 25, 2022:1–4. doi:10.1080/09273948.2022.2114915.
- Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol. 2021;139(10):1131–1135. doi:10.1001/jamaophthalmol.2021.3477.
- Valenzuela DA, Groth S, Taubenslag KJ, Gangaputra S. Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination. Am J Ophthalmol Case Rep. 2021;1(24):101200. doi:10.1016/j.ajoc.2021.101200.
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase ½, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi:10.1016/S0140-6736(20)31604-4.
- Vojdani A, Kharrazian D. Potential antigenic crossreactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi:10.1016/j.clim.2020.108480.
- Vadalà M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J. 2017;8:295–311. doi:10.1007/s13167-017-0101-y.